

<u>DB Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	l13 and lysosom\$	1	<u>L14</u>
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	l11 and inhibit\$	31	<u>L13</u>
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	l11 and inhibit\$	31	<u>L12</u>
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	l1 and ucp	47	<u>L11</u>
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	l4 and treat\$ and antigen\$	13	<u>L10</u>
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	l4 and treat\$ and antigen\$	13	<u>L9</u>
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	l4 and (binding with peptide\$)	6	<u>L8</u>
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	l4 and (binding with peptide\$)	6	<u>L7</u>
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	l4 same mutat\$	2	<u>L6</u>
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	l4 and (dominant with negative)	1	<u>L5</u>
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	l1 same inhibit\$	25	<u>L4</u>
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	l1 same inhibit\$	25	<u>L3</u>
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	l1 and lysosom\$	2	<u>L2</u>
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	uncoupling with protein	108	<u>L1</u>

WEST

Help

Logout

Interrupt

Main Menu

Search Form

Posting Counts

Show S Numbers

Edit S Numbers

Preferences

Search Results -

Terms	Documents
l4 and treat\$ and antigen\$	13

Database:

US Patents Full-Text Database
 US Pre-Grant Publication Full-Text Database
 JPO Abstracts Database
 EPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Refine Search:

l4 and treat\$ and antigen\$

Clear

Search History**Today's Date: 7/6/2001**

<u>DB Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	l4 and treat\$ and antigen\$	13	<u>L10</u>
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	l4 and treat\$ and antigen\$	13	<u>L9</u>
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	l4 and (binding with peptide\$)	6	<u>L8</u>
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	l4 and (binding with peptide\$)	6	<u>L7</u>
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	l4 same mutat\$	2	<u>L6</u>
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	l4 and (dominant with negative)	1	<u>L5</u>
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	l1 same inhibit\$	25	<u>L4</u>
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	l1 same inhibit\$	25	<u>L3</u>
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	l1 and lysosom\$	2	<u>L2</u>
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	uncoupling with protein	108	<u>L1</u>

WEST**End of Result Set**

Generate Collection

L11: Entry 13 of 13

File: DWPI

Aug 7, 1998

DERWENT-ACC-NO: 1998-413823

DERWENT-WEEK: 199901

COPYRIGHT 2001 DERWENT INFORMATION LTD

TITLE: Method for treating disease associated with altered UCP-2 expression - by administering agent which enhances or inhibits UCP-2 activity, effectively to treat obesity, diabetes, fever, hyperthermia, cachexia etc.

INVENTOR: BOUILLAUD, F; COLLINS, S A ; RICQUIER, D ; SELDIN, M F ; SURWIT, R S ; WARDEN, C H

PATENT-ASSIGNEE:

ASSIGNEE

CENT NAT RECH SCI CENT RECH SUR ENDOCRIN

UNIV CALIFORNIACI CENT RECH SUR ENDOCRIN

UNIV DUKEFORNIACI CENT RECH SUR ENDOCRIN

CODE

NAREN

REGC

UYDUN

PRIORITY-DATA: 1997US-0034960 (January 15, 1997)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
AU 9728097 A	August 7, 1998	N/A	000	A61K048/00
WO 9831396 A1	July 23, 1998	E	098	A61K048/00

DESIGNATED-STATES: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AT BE CH DE DK EA ES FI FR GB GH GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG

APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
AU 9728097A	April 22, 1997	1997AU-0028097	N/A
AU 9728097A		WO 9831396	Based on
WO 9831396A1	April 22, 1997	1997WO-US06864	N/A

INT-CL (IPC): A61K 48/00; C07K 14/47; C12N 1/15; C12N 1/21; C12N 5/10; C12N 15/09; C12N 15/12; C12P 21/02

ABSTRACTED-PUB-NO: WO 9831396A

BASIC-ABSTRACT:

Method for treating a disease or disorder associated with diminished (or elevated) uncoupling protein-2 (UCP2) expression or activity, comprises administering an agent that enhances (or inhibits) UCP2 expression or activity sufficient to effect the treatment.

Also claimed are:

(1) a method for screening a compound for its ability to modulate UCP2 expression or activity comprising:

(a) contacting a cell that expresses UCP2 with the compound under conditions such that modulation of UCP2 expression or activity can occur, and

(b) measuring UCP2 expression or activity in the presence and absence of the compound and determining whether modulation is effected;

(2) isolated mammalian UCP2, or a fragment of at least 5 amino acids, preferably with the 309 amino acid human UCP2 sequence given in the specification;

(3) an isolated nucleic acid sequence encoding mammalian UCP2, or a fragment of at least 15 nucleotides in length;

(4) a recombinant molecule comprising a vector and the nucleic acid of (3);

(5) a host cell comprising the recombinant molecule of (4);

(6) an antibody specific for UCP2 or an antigenic binding fragment of it;

(7) an antisense construct comprising a vector and a nucleic acid operably linked to a promoter, where the nucleic acid is oriented with respect to the promoter such that the transcript of the nucleic acid selectively hybridises to UCP2 mRNA, and

(8) a host cell comprising the construct of (7).

USE - An agent which enhances UCP2 expression can be used to treat obesity, diabetes, syndrome X, hypothermia, hyperinsulinaemia, or glucose intolerance.

An inhibitor of UCP2 is used to treat wasting, anorexia, inflammation, cachexia, fever or hyperthermia.

The host cell of (4) can be used to produce UCP2. The constructs of (4) and (7) can both be used in the method (all claimed).

CHOSEN-DRAWING: Dwg.0/11

TITLE-TERMS: METHOD TREAT DISEASE ASSOCIATE ALTER EXPRESS ADMINISTER AGENT ENHANCE INHIBIT ACTIVE EFFECT TREAT OBESITY DIABETES FEVER HYPERTHERMIA CACHEXIA

DERWENT-CLASS: B04 D16

CPI-CODES: B04-E02F; B04-E06; B04-E08; B04-F0100E; B04-G01; B04-N02; B14-C03; B14-C05; B14-E11; B14-E12; B14-S04; D05-H09; D05-H11A; D05-H12A; D05-H12D2; D05-H12E; D05-H14; D05-H17A;

CHEMICAL-CODES:

Chemical Indexing M1 *01*

Fragmentation Code

M423 M710 M903 N102 P731 P816 P820 P831 Q233 Q505

V752

SECONDARY-ACC-NO:

CPI Secondary Accession Numbers: C1998-124872

WEST

Generate Collection

L17: Entry 25 of 31

File: DWPI

Jul 31, 2000

DERWENT-ACC-NO: 2000-452407

DERWENT-WEEK: 200050

COPYRIGHT 2001 DERWENT INFORMATION LTD

TITLE: DNA with promoter region containing regulator sequence of uncoupling protein-2 (UCP-2), applicable in screening anti-obesity, anti-diabetic, hypotensive, anti-hyperlipidemic and anti-pyretic drugs for use in therapy

INVENTOR: IGAKI, S; KOBAYASHI, M ; TOYODA, Y

PATENT-ASSIGNEE:

ASSIGNEE

CODE

TAKEDA CHEM IND LTD

TAKE

PRIORITY-DATA: 1998JP-0366719 (December 24, 1998)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
AU 200017980 A	July 31, 2000	N/A	000	C12N015/85
WO 200039315 A1	July 6, 2000	J	043	C12N015/85
JP 2000236886 A	September 5, 2000	N/A	015	C12N015/09

DESIGNATED-STATES: AE AL AM AU AZ BA BB BG BR BY CA CN CR CU CZ DM EE GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LV MA MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT TZ UA US UZ VN YU ZA AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SL SZ TZ UG ZW

APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
AU 200017980A	December 22, 1999	2000AU-0017980	N/A
AU 200017980A		WO 200039315	Based on
WO 200039315A1	December 22, 1999	1999WO-JP07198	N/A
JP2000236886A	December 22, 1999	1999JP-0364724	N/A

INT-CL (IPC): A61K 31/711; A61K 35/00; A61K 38/00; A61K 45/00; A61K 48/00; A61P 3/04; A61P 3/06; A61P 3/10; A61P 9/12; A61P 29/00; C12N 1/21; C12N 5/10; C12N 15/09; C12N 15/85; C12Q 1/00; C12Q 1/02; G01N 33/15; G01N 33/50; C12N 1/21; C12N 5/10; C12N 15/09; C12N 15/09; C12R 1/19; C12R 1/19; C12R 1/91; C12R 1/91

ABSTRACTED-PUB-NO: WO 200039315A

BASIC-ABSTRACT:

NOVELTY - A DNA comprising a promoter region with the regulator sequence of uncoupling protein-2 (UCP-2) is new. It is applicable in screening anti-obesity, anti-diabetic, hypotensive, anti-hyperlipidemic and anti-pyretic drugs for use in therapy.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

- (1) a recombinant vector containing the DNA;
- (2) a transformant transformed with the recombinant vector;
- (3) a screening method for compounds or salts that can promote or inhibit the UCP-2 promoter activity by using the transformant;
- (4) a screening method for compounds or salts that can promote or inhibit heat production by using the transformant;
- (5) a method for screening anti-obesity, anti-diabetic, hypotensive, anti-hyperlipidemic or anti-pyretic drugs by using the transformant;
- (6) a kit for screening compounds or salts that can promote or inhibit the UCP-2 promoter activity or heat production containing the transformant; and
- (7) compounds or their salts that can promote or inhibit the UCP-2 promoter activity or heat production as screened by the methods.

ACTIVITY - Uncoupling protein-2 activity.

MECHANISM OF ACTION - Promoter or inhibitor of UCP-2 activity.

USE - The DNA and its transformant can be used to screen anti-obesity, anti-diabetic, hypotensive, anti-hyperlipidemic and anti-pyretic drugs (claimed), e.g. in the form of inhibitor and promoters in drug compositions for use in therapy.

DESCRIPTION OF DRAWING(S) - Luciferase activity obtained during detection of promoter activity of human UCP-2 gene, by plotting luciferase activity (c.p.s) against plasmid over 24-72 hrs.

CHOSEN-DRAWING: Dwg.7/10

TITLE-TERMS: DNA PROMOTE REGION CONTAIN REGULATE SEQUENCE UNCOUPLE PROTEIN
APPLY SCREEN ANTI OBESITY ANTI DIABETES HYPOTENSIVE ANTI ANTI PYRETIC DRUG
THERAPEUTIC

DERWENT-CLASS: B04 D16 S03

CPI-CODES: B04-E02F; B04-E03F; B04-E08; B04-F0100E; B11-C08E3; B11-C08E5;
B12-K04E; B12-K04F; D05-H09; D05-H12A; D05-H18B;

EPI-CODES: S03-E14H; S03-E14H9;

CHEMICAL-CODES:

Chemical Indexing M1 *01*

Fragmentation Code

M423 M710 M750 M781 M905 N102 P831 Q233 Q505

Specific Compounds

A00NSA A00NSD A00NSN

Chemical Indexing M6 *02*

Fragmentation Code

M905 P831 Q233 Q505 R515 R521 R627 R633 R639

SECONDARY-ACC-NO:

CPI Secondary Accession Numbers: C2000-137956

Non-CPI Secondary Accession Numbers: N2000-336793

WEST**End of Result Set**

Generate Collection

L17: Entry 31 of 31

File: DWPI

Aug 7, 1998

DERWENT-ACC-NO: 1998-413823

DERWENT-WEEK: 199901

COPYRIGHT 2001 DERWENT INFORMATION LTD

TITLE: Method for treating disease associated with altered UCP-2 expression - by administering agent which enhances or inhibits UCP-2 activity, effectively to treat obesity, diabetes, fever, hyperthermia, cachexia etc.

INVENTOR: BOUILLAUD, F; COLLINS, S A ; RICQUIER, D ; SELDIN, M F ; SURWIT, R S ; WARDEN, C H

PATENT-ASSIGNEE:

ASSIGNEE

CENT NAT RECH SCI CENT RECH SUR ENDOCRIN

UNIV CALIFORNIACI CENT RECH SUR ENDOCRIN

UNIV DUKEFORNIACI CENT RECH SUR ENDOCRIN

CODE

NAREN

REGC

UYDUN

PRIORITY-DATA: 1997US-0034960 (January 15, 1997)

PATENT-FAMILY:

PUB-NO

PUB-DATE

LANGUAGE

PAGES

MAIN-IPC

AU 9728097 A

August 7, 1998

N/A

000

A61K048/00

WO 9831396 A1

July 23, 1998

E

098

A61K048/00

DESIGNATED-STATES: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AT BE CH DE DK EA ES FI FR GB GH GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG

APPLICATION-DATA:

PUB-NO

APPL-DATE

APPL-NO

DESCRIPTOR

AU 9728097A

April 22, 1997

1997AU-0028097

N/A

AU 9728097A

WO 9831396

Based on

WO 9831396A1

April 22, 1997

1997WO-US06864

N/A

INT-CL (IPC): A61K 48/00; C07K 14/47; C12N 1/15; C12N 1/21; C12N 5/10; C12N 15/09; C12N 15/12; C12P 21/02

ABSTRACTED-PUB-NO: WO 9831396A

BASIC-ABSTRACT:

Method for treating a disease or disorder associated with diminished (or elevated) uncoupling protein-2 (UCP2) expression or activity, comprises administering an agent that enhances (or inhibits) UCP2 expression or activity sufficient to effect the treatment.

Also claimed are:

- (1) a method for screening a compound for its ability to modulate UCP2 expression or activity comprising:
 - (a) contacting a cell that expresses UCP2 with the compound under conditions such that modulation of UCP2 expression or activity can occur, and
 - (b) measuring UCP2 expression or activity in the presence and absence of the compound and determining whether modulation is effected;
- (2) isolated mammalian UCP2, or a fragment of at least 5 amino acids, preferably with the 309 amino acid human UCP2 sequence given in the specification;
- (3) an isolated nucleic acid sequence encoding mammalian UCP2, or a fragment of at least 15 nucleotides in length;
- (4) a recombinant molecule comprising a vector and the nucleic acid of (3);
- (5) a host cell comprising the recombinant molecule of (4);
- (6) an antibody specific for UCP2 or an antigenic binding fragment of it;
- (7) an antisense construct comprising a vector and a nucleic acid operably linked to a promoter, where the nucleic acid is oriented with respect to the promoter such that the transcript of the nucleic acid selectively hybridises to UCP2 mRNA, and
- (8) a host cell comprising the construct of (7).

USE - An agent which enhances UCP2 expression can be used to treat obesity, diabetes, syndrome X, hypothermia, hyperinsulinaemia, or glucose intolerance.

An inhibitor of UCP2 is used to treat wasting, anorexia, inflammation, cachexia, fever or hyperthermia.

The host cell of (4) can be used to produce UCP2. The constructs of (4) and (7) can both be used in the method (all claimed).

CHOSEN-DRAWING: Dwg.0/11

TITLE-TERMS: METHOD TREAT DISEASE ASSOCIATE ALTER EXPRESS ADMINISTER AGENT
ENHANCE INHIBIT ACTIVE EFFECT TREAT OBESITY DIABETES FEVER HYPERTHERMIA
CACHEXIA

DERWENT-CLASS: B04 D16

CPI-CODES: B04-E02F; B04-E06; B04-E08; B04-F0100E; B04-G01; B04-N02; B14-C03;
B14-C05; B14-E11; B14-E12; B14-S04; D05-H09; D05-H11A; D05-H12A; D05-H12D2;
D05-H12E; D05-H14; D05-H17A;

CHEMICAL-CODES:

Chemical Indexing M1 *01*

Fragmentation Code

M423 M710 M903 N102 P731 P816 P820 P831 Q233 Q505

V752

SECONDARY-ACC-NO:

CPI Secondary Accession Numbers: C1998-124872

WEST[Generate Collection](#)**Search Results - Record(s) 1 through 10 of 31 returned.**☐ 1. Document ID: US 6248561 B1

L17: Entry 1 of 31

File: USPT

Jun 19, 2001

US-PAT-NO: 6248561

DOCUMENT-IDENTIFIER: US 6248561 B1

TITLE: UCP3 genes

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 2. Document ID: US 6197580 B1

L17: Entry 2 of 31

File: USPT

Mar 6, 2001

US-PAT-NO: 6197580

DOCUMENT-IDENTIFIER: US 6197580 B1

TITLE: Transcriptional regulation of the human .beta.3-adrenergic receptor gene

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 3. Document ID: US 6187560 B1

L17: Entry 3 of 31

File: USPT

Feb 13, 2001

US-PAT-NO: 6187560

DOCUMENT-IDENTIFIER: US 6187560 B1

TITLE: Polynucleotides and polypeptides belonging to the uncoupling proteins family

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 4. Document ID: US 6172279 B1

L17: Entry 4 of 31

File: USPT

Jan 9, 2001

US-PAT-NO: 6172279

DOCUMENT-IDENTIFIER: US 6172279 B1

TITLE: Plant gene construct encoding a protein capable of disrupting the biogenesis of viable pollen

Full	Title	Citation	Front	Review	Classification	Date	Reference
------	-------	----------	-------	--------	----------------	------	-----------

KWIC	Draw Desc	Image
------	-----------	-------

☐ 5. Document ID: US 6166192 A

L17: Entry 5 of 31

File: USPT

Dec 26, 2000

US-PAT-NO: 6166192

DOCUMENT-IDENTIFIER: US 6166192 A

TITLE: PGC-1, a novel brown fat PPAR.gamma. coactivator

Full	Title	Citation	Front	Review	Classification	Date	Reference
------	-------	----------	-------	--------	----------------	------	-----------

KWIC	Draw Desc	Image
------	-----------	-------

☐ 6. Document ID: US 6132724 A

L17: Entry 6 of 31

File: USPT

Oct 17, 2000

US-PAT-NO: 6132724

DOCUMENT-IDENTIFIER: US 6132724 A

TITLE: Allelic polygene diagnosis of reward deficiency syndrome and treatment

Full	Title	Citation	Front	Review	Classification	Date	Reference
------	-------	----------	-------	--------	----------------	------	-----------

KWIC	Draw Desc	Image
------	-----------	-------

☐ 7. Document ID: US 6124439 A

L17: Entry 7 of 31

File: USPT

Sep 26, 2000

US-PAT-NO: 6124439

DOCUMENT-IDENTIFIER: US 6124439 A

TITLE: OB polypeptide antibodies and method of making

Full	Title	Citation	Front	Review	Classification	Date	Reference
------	-------	----------	-------	--------	----------------	------	-----------

KWIC	Draw Desc	Image
------	-----------	-------

☐ 8. Document ID: US 6124448 A

L17: Entry 8 of 31

File: USPT

Sep 26, 2000

US-PAT-NO: 6124448

DOCUMENT-IDENTIFIER: US 6124448 A

TITLE: Nucleic acid primers and probes for the mammalian OB gene

Full	Title	Citation	Front	Review	Classification	Date	Reference
------	-------	----------	-------	--------	----------------	------	-----------

KWIC	Draw Desc	Image
------	-----------	-------

☐ 9. Document ID: US 6121017 A

L17: Entry 9 of 31

File: USPT

Sep 19, 2000

US-PAT-NO: 6121017

DOCUMENT-IDENTIFIER: US 6121017 A

TITLE: Compositions for the treatment of body weight disorders, including obesity

Full	Title	Citation	Front	Review	Classification	Date	Reference
------	-------	----------	-------	--------	----------------	------	-----------

KWIC	Draw Desc	Image
------	-----------	-------

☐ 10. Document ID: US 6071747 A

L17: Entry 10 of 31

File: USPT

Jun 6, 2000

US-PAT-NO: 6071747

DOCUMENT-IDENTIFIER: US 6071747 A

TITLE: Immortalized cell lines from human adipose tissue, process for preparing same and applications thereof

Full	Title	Citation	Front	Review	Classification	Date	Reference
------	-------	----------	-------	--------	----------------	------	-----------

KWIC	Draw Desc	Image
------	-----------	-------

Generate Collection

Terms	Documents
l11 and inhibit\$	31

Display

10

Documents, starting with Document:

11

Display Format:

TI

Change Format
